Compare Neurocrine Biosciences Inc (NBIX) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.35. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| NBIX | QCLN | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $68.47 |
52-Week Low | $123.10 | $37.69 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
QCLN trades at $50.57, up 2.31% today, with a bullish technical signal overall despite bearish moving averages. The ETF is positioned to benefit from global renewable energy acceleration driven by geopolitical tensions and rising data center power demand. Recent news highlights its sensitivity to U.S. political outcomes and federal clean energy policy, with historical outperformance ahead of midterm elections.
The outlook is supported by structural tailwinds in clean energy adoption, but risks include regulatory uncertainty and permit delays under current U.S. administration. Investment appeal hinges on policy continuity and execution of global renewable projects, with volatility expected around political developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
